Skeletal fractures due to low bone mass are projected to increase markedly as the United States population ages. Identifying and providing care to individuals at greatest risk for fracture is therefore of paramount importance. While the incidence of bone loss and fractures increases with aging, so too does the risk for developing a monoclonal gammopathy, a collection of plasma cell disorders which includes monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). MGUS is the most common monoclonal gammopathy, affecting roughly 3.2% of adults aged 50 and older (correlating to nearly 3 million current US residents). While osteolytic lesions and fractures are a well-recognized complication of MM, far less is known about the skeletal health of subjects with MGUS and SMM. Recent data demonstrate that subjects with MGUS have an increased incidence of fractures. Our preliminary data demonstrate that MGUS subjects have significantly diminished bone mass, altered bone microstructure, and increased serum levels of factors [Dickkopf1 and macrophage inflammatory protein 1-1)] known to correlate with osteolytic lesions in MM. The objectives of this application are to characterize the bone changes that occur in humans with monoclonal gammopathies at both a skeletal level (through both epidemiologic and imaging-based approaches) and a cellular level (by determining if alterations in osteoblast (OB) and osteoclast (OC) activity across the entire spectrum of monoclonal gammopathies result from common mechanisms).
Aim 1 seeks to examine bone microstructure (using high-resolution peripheral quantitative computed tomography) in patients with SMM and MM, and to determine if SMM is associated with an increased fracture incidence. Osteolytic lesions in MM bone disease result from both inhibition of OB progenitor cell differentiation and enhancement of OC lineage cell differentiation.
Aim 2 seeks to determine the signaling pathways within OB and OC progenitor cells which are altered in MM, and whether these same alterations also occur in OB and OC lineage cells in MGUS and SMM. This will be determined by isolating highly-enriched OB and OC progenitor cell populations from the bone marrow of subjects with MGUS, SMM, or MM and matched controls, and determining changes in gene expression along both focused and potentially novel pathways.
Aim 3 will focus on whether in vitro, OB and OC progenitor cell differentiation and activity can be modulated by selective inhibition of the signaling pathways identified in Aim 2 to prevent OB inhibition or OC stimulation induced by culture of OB and OC progenitor cells with BM plasma from MGUS, SMM, or MM subjects.

Public Health Relevance

A more thorough understanding of the mechanisms underlying the increased fracture risk that occurs in patients with monoclonal gammopathies (MGUS, SMM, and MM) is fundamentally important if we are to provide improved care for the approximately 3 million Americans affected by this class of related plasma cell disorders. The work described in this application offers a unique opportunity to study bone progenitor cells within the bone marrow microenvironment, the site to which plasma cells localize and grow, leading to bone loss and increased fracture risk. The proposed studies will provide both a skeletal phenotypic and molecular assessment of monoclonal gammopathy bone disease in humans, and will allow us to determine if common mechanisms of osteoblast suppression and osteoclast stimulation occur in pre-malignant (MGUS and SMM) as well as malignant (MM) monoclonal gammopathies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08AR059138-05
Application #
8705857
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Chen, Faye H
Project Start
2010-08-01
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$122,850
Indirect Cost
$9,100
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Drake, Matthew T; Farr, Joshua N (2014) Inhibitors of sclerostin: emerging concepts. Curr Opin Rheumatol 26:447-52
Drake, Matthew T (2014) unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res 29:2529-33
Drake, Matthew T (2014) Vitamin D and the goldilocks principle: too little, too much, or just right? J Clin Endocrinol Metab 99:1164-6
Farr, Joshua N; Zhang, Wei; Kumar, Shaji K et al. (2014) Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood 123:647-9
Drake, Matthew T (2013) Osteoporosis and cancer. Curr Osteoporos Rep 11:163-70
Kennel, Kurt A; Drake, Matthew T (2013) Vitamin D in the cancer patient. Curr Opin Support Palliat Care 7:272-7
Ng, Alvin C; Khosla, Sundeep; Charatcharoenwitthaya, Natthinee et al. (2011) Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1? levels in patients with MGUS. Blood 118:6529-34